- Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months2022 | 1. lékařská fakulta
- Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS2012 | 1. lékařská fakulta
- Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis2017 | 1. lékařská fakulta, 3. lékařská fakulta
- Neuromyelitis optica a poruchy jejího širšího spektra - retrospektivní analýza klinických a paraklinických nálezů2015 | 1. lékařská fakulta
- Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis2016 | 1. lékařská fakulta
- Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences2023 | 1. lékařská fakulta
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | 1. lékařská fakulta
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | 2. lékařská fakulta
- Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years2020 | 1. lékařská fakulta
- Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals2021 | 1. lékařská fakulta
- Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts2021 | 1. lékařská fakulta
- Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS2021 | 3. lékařská fakulta, 2. lékařská fakulta, Lékařská fakulta v Plzni, Lékařská fakulta v Hradci Králové
- Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers2023 | 1. lékařská fakulta
- Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome2012 | 1. lékařská fakulta
- Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry2022 | 1. lékařská fakulta
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study2020 | 1. lékařská fakulta
- Hematopoietic stem cell transplatation for multiple scerosis: A retrospective multicenter study2002 | 1. lékařská fakulta, 3. lékařská fakulta
- Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS2019 | 1. lékařská fakulta, 3. lékařská fakulta, 2. lékařská fakulta, Ústřední knihovna, Lékařská fakulta v Plzni, Lékařská fakulta v Hradci Králové
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study2017 | 1. lékařská fakulta
- Early clinical markers of aggressive multiple sclerosis2020 | 1. lékařská fakulta
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | 1. lékařská fakulta, 3. lékařská fakulta
- Měření atrofie corpus callosum a porovnání s ostatními metodami monitorace roztroušené sklerózy2012 | 1. lékařská fakulta
- Hematopoietic stem cell transplantation for multiple sclerosis2005 | 3. lékařská fakulta
- Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis2018 | 1. lékařská fakulta
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension2018 | 1. lékařská fakulta
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | 1. lékařská fakulta
- Snížená denzita kostního minerálu u žen s roztroušenou sklerózou2013 | 1. lékařská fakulta, Farmaceutická fakulta v Hradci Králové
- Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis2021 | 1. lékařská fakulta
- Is breastfeeding in MS harmful or not? An answer from real-world Czech data2023 | 1. lékařská fakulta, 3. lékařská fakulta, 2. lékařská fakulta, Lékařská fakulta v Plzni, Lékařská fakulta v Hradci Králové
- Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network2023 | 1. lékařská fakulta
